Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders
Recruiting
Phase 2
Phase 3
Interventional Study
Poor Response to Ovulation Induction
Infertility, Female
Ovarian Insufficiency
Ovarian Failure
Reproductive Sterility
Ovary; Anomaly
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 35 – 47
- Sex
- Female
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Genesis Athens Clinic · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Autologous platelet rich plasma (PRP) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (ICSI) treatment.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Poor Ovarian Response according to Bologna Criteria (fulfilling 2 out of 3 of the following):
1. Age ≥ 40 years
2. AMH \< 1.1 ng/ml OR AFC \< 7
3. ≤ 3 oocytes with a conventional stimulation protocol
* Discontinuation of any complementary/adjuvant treatment including hormon…
Contacts